Press

Societal CDMO Announces Pricing of $8.3 Million Public Offering of Common Stock

Aug 24 • 3 min read

Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (“CDMO”) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the pricing of its previously announced underwritten public offering of 20,750,000 shares of its common stock (or common stock equivalents) at a public offering price of…

Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD

Aug 24 • 4 min read

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that its subsidiary Psychennex Pty Ltd has commenced preparations of an investigational new drug (‘IND’) application to the U.S. Food and Drug Administration (‘FDA’) for the…

Core One Labs : Commends Study Exploring Psychedelics’ Efficacy in Providing Relief for Chronic Pain Conditions

Aug 24 • 3 min read

Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One“) applauds a recent survey study published in the European Journal of Pain, which suggests that psychedelic substances could offer potential therapeutic value in addressing specific chronic pain conditions. By conducting an extensive survey among 170 individuals dealing with chronic pain and who met…

Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million

Aug 24 • 6 min read

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today that it has renewed its previously established at-the-market equity program (the “ATM Program”) that allows Cybin to issue and sell up to US$35,000,000 of common shares (“Shares”)…

MindBio Therapeutics Corp. Begins Dosing Mb22001 in Phase 2 Clinical Trial in World’s First Take-Home Microdosing Study in Patients with Depression

Aug 24 • 2 min read

MindBio Therapeutics Corp. (CSE:MBIO) announce the first doses of MB22001 have been administered to patients in this landmark microdosing study in depressed patients. This trial is a world first and remains the only clinical trial in the world to be approved for take-home use of LSD. MB22001 is MindBio’s proprietary titratable form of Lysergic Acid…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435